Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial: A Modeling Study.

Publication Type:

Journal Article


Annals of internal medicine, Volume 160, Issue 9, p.594-602 (2014)


2014, May 2014, Public Health Sciences Division


The findings of the Women's Health Initiative (WHI) estrogen plus progestin (E+P) trial led to a substantial reduction in use of combined hormone therapy (cHT) among postmenopausal women in the United States. The economic effect of this shift has not been evaluated relative to the trial's $260 million cost (2012 U.S. dollars).